BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38030183)

  • 21. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
    Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
    Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
    Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
    Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.
    Baboudjian M; Gondran-Tellier B; Touzani A; Martini A; Diamand R; Roche JB; Lacetera V; Beauval JB; Roumeguère T; Simone G; Benamran D; Fourcade A; Fiard G; van den Bergh RCN; Peltier A; Ploussard G
    Eur Urol Oncol; 2023 Aug; 6(4):406-413. PubMed ID: 36280445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate MRI evolution in clinical practice: Audit of tumour detection and staging versus prostatectomy with staged introduction of multiparametric MRI and Prostate Imaging Reporting and Data System v2 reporting.
    Raeside M; Low A; Cohen P; Sutherland P; Gormly K
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):487-494. PubMed ID: 30951248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
    Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
    Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy.
    Peng Q; Xu L; Zhang G; Zhang D; Zhang J; Zhang X; Bai X; Chen L; Jin Z; Sun H
    Cancer Imaging; 2023 Nov; 23(1):113. PubMed ID: 38008745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients.
    Wang H; Ruan M; Wang H; Li X; Hu X; Liu H; Zhou B; Song G
    Transl Androl Urol; 2021 Feb; 10(2):584-593. PubMed ID: 33718061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Favorable intermediate risk prostate cancer with biopsy Gleason score of 6.
    Oh JJ; Ahn H; Hwang SI; Lee HJ; Choe G; Lee S; Lee H; Byun SS; Hong SK
    BMC Urol; 2021 Apr; 21(1):52. PubMed ID: 33820533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
    Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
    Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
    Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
    World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.